Avid Bioservices Inc (CDMO)

[biopharm]

Yet, I don't understand why tonite should be any different then any other nite. Why these new orders? (See Bottom of this post). Is somebody expecting a potential PPHM RUN/BreakOut?
These orders could have been placed as GoodTilCancelled?

Well, all I am trying to say is, I noticed something peculiar and out of the ordinary tonite, and I wanted to post it to the board before it disappeared, for any that might be interested, for what it is worth...
...

thanks for the info and when things change its best to chase after every single lead and see what turns up. I wonder what will turn up with BeiGene, where SA Jedd Wolchok popped up at....and so much secrecy like PPHM

---------------------

Currently we are engaged in partnering/in-licensing discussions related to the following programs:

MEKi
ERKi
PI3K-delta
BCL-2i
IRAK4i
LAG3i
CD-27i
CD-137i
Immuno-modulator inhibitors that are potentially synergistic with PD-1/PD-L1 mAbs

If you would like additional information on partnering with BeiGene, please contact our business development team at [e-mail]

http://www.beigene.com/business-development/overview/

---------------------------------

Combination Solutions:

Please read: "ENHANCED BY UNDISCLOSED I-O AGENTS" on the graph in the link below:

http://www.beigene.com/our-science/combination-solutions/

--------------------------------

Scientific Advisory Board

Ron Levy, M.D.

Professor of Medicine, Director of Lymphoma Program, Former Chief of Division of Oncology at Stanford
Member of National Academy of Sciences & Institute of Medicine
More than 20 years research on mAb to B cells; first to successfully treat human lymphoma with a monoclonal antibody, and went on to make important contributions to the development of rituximab (Rituxan®), for treatment of patients with resistant low-grade lymphomas



Neal Rosen, M.D., Ph.D.


Member of Department of Medicine and Head of Developmental Therapeutics at Memorial Sloan-Kettering Cancer Center
Professor of Pharmacology, Cell Biology and Medicine at Cornell University
Played important role in developing tyrosine kinase-mediated signaling inhibitors and pioneered concept that cancer cells are dependent on cellular machinery for protein folding



Charles Sawyers, M.D.


President-elect of the AACR; former President of the American Society of Clinical Investigation
Serves on the National Cancer Institute’s Board of Scientific Counselors
Member of the Institute of Medicine of the National Academy of Sciences


David Schenkein, M.D.

Agios (AGIO) Chief Executive Officer
Adjunct Attending Physician in Hematology at Tufts Medical Center
Member of the board of directors for the Biotechnology Industry Organization (BIO)
Formerly at Genentech, Millennium Pharma
Served as Adjunct Clinical Professor of Medical Oncology at Stanford


Xiaodong Wang, Ph.D.
Founder & Chairman SAB

Director of National Institute of Biological Sciences in Beijing
Former Howard Hughes Investigator, Distinguished Chair of Biomedical Sciences and Professor of Biochemistry at University of Texas-Southwestern
Member of National Academy of Sciences, USA
Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in U.S.


Jedd Wolchok, M.D., Ph.D.

Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK)
Associate Director of the Ludwig Center for Cancer Immunotherapy and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair for Clinical Investigation at MSK
Associate Director of the CRI Scientific Advisory Council
Co-editor of the journal Cytotherapy
M.D. and a Ph.D. from New York University

http://beigeneltd.com/company/scientific-advisory-board/


-------------------------------

SEC Filings:
http://ir.beigene.com/phoenix.zhtml?c=254246&p=irol-sec&secCat01.1_rs=1&secCat01.1_rc=20

------------------------------

I think we are in for an exciting Feb of 2016 that we may not forget